The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing

丝氨酸羟甲基转移酶-2 (SHMT2) 通过表观遗传肿瘤抑制基因沉默启动淋巴瘤的发生发展

阅读:5
作者:Sara Parsa # ,Ana Ortega-Molina # ,Hsia-Yuan Ying ,Man Jiang ,Matt Teater ,Jiahui Wang ,Chunying Zhao ,Ed Reznik ,Joyce P Pasion ,David Kuo ,Prathibha Mohan ,Shenqiu Wang ,Jeannie M Camarillo ,Paul M Thomas ,Neeraj Jain ,Javier Garcia-Bermudez ,Byoung-Kyu Cho ,Wayne Tam ,Neil L Kelleher ,Nicholas Socci ,Ahmet Dogan ,Elisa De Stanchina ,Giovanni Ciriello ,Michael R Green ,Sheng Li ,Kivanc Birsoy ,Ari M Melnick ,Hans-Guido Wendel

Abstract

Cancer cells adapt their metabolic activities to support growth and proliferation. However, increased activity of metabolic enzymes is not usually considered an initiating event in the malignant process. Here, we investigate the possible role of the enzyme serine hydroxymethyltransferase-2 (SHMT2) in lymphoma initiation. SHMT2 localizes to the most frequent region of copy number gains at chromosome 12q14.1 in lymphoma. Elevated expression of SHMT2 cooperates with BCL2 in lymphoma development; loss or inhibition of SHMT2 impairs lymphoma cell survival. SHMT2 catalyzes the conversion of serine to glycine and produces an activated one-carbon unit that can be used to support S-adenosyl methionine synthesis. SHMT2 induces changes in DNA and histone methylation patterns leading to promoter silencing of previously uncharacterized mutational genes, such as SASH1 and PTPRM. Together, our findings reveal that amplification of SHMT2 in cooperation with BCL2 is sufficient in the initiation of lymphomagenesis through epigenetic tumor suppressor silencing.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。